Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015', provides an overview of the Genital Warts (Condylomata Acuminata)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Genital Warts (Condylomata Acuminata) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Genital Warts (Condylomata Acuminata) Overview 8
Therapeutics Development 9
Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview 9
Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis 10
Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies 11
Genital Warts (Condylomata Acuminata) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Genital Warts (Condylomata Acuminata) - Products under Development by Companies 15
Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development 16
Agilvax, Inc. 16
Anaconda Pharma 17
Biogenomics Limited 18
BioMAS Ltd. 19
Foamix Pharmaceuticals Ltd. 20
G&E Herbal Biotechnology Co., Ltd. 21
Helix BioPharma Corp. 22
LEO Pharma A/S 23
MediGene AG 24
NanoViricides, Inc. 25
Novan, Inc. 26
Tamir Biotechnology, Inc. 27
Genital Warts (Condylomata Acuminata) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AP-611074 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AS-101 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AX-03 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HerpeCide-I - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
imiquimod - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ingenol mebutate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
interferon alfa-2b (recombinant) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
interferon alpha-2b (recombinant) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PP-210 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ranpirnase - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SB-206 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
sinecatechins - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SRT-100 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates 56
Genital Warts (Condylomata Acuminata) - Dormant Projects 59
Genital Warts (Condylomata Acuminata) - Discontinued Products 60
Genital Warts (Condylomata Acuminata) - Product Development Milestones 61
Featured News & Press Releases 61
Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries 61
Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries 61
Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen 62
Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland 62
Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen in United Kingdom and Ireland 62
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden 63
Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia 64
Oct 01, 2013: Medigene announces market launch of Veregen in Taiwan 64
Sep 10, 2013: Medigene's Drug Veregen receives market approval in Canada 64
Jul 29, 2013: Medigene: Market launch of Veregen in the Netherlands started 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2015 9
Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2015 16
Genital Warts (Condylomata Acuminata) - Pipeline by Anaconda Pharma, H1 2015 17
Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2015 18
Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2015 19
Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 20
Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015 21
Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2015 22
Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2015 23
Genital Warts (Condylomata Acuminata) - Pipeline by MediGene AG, H1 2015 24
Genital Warts (Condylomata Acuminata) - Pipeline by NanoViricides, Inc., H1 2015 25
Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2015 26
Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Stage and Target, H1 2015 30
Number of Products by Stage and Mechanism of Action, H1 2015 32
Number of Products by Stage and Route of Administration, H1 2015 34
Number of Products by Stage and Molecule Type, H1 2015 36
Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2015 56
Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2015 59
Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2015 60